Patents by Inventor Michael Franti

Michael Franti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REVERSE GENETICS SYSTEMS
    Publication number: 20120270321
    Abstract: The invention provides various reverse genetics systems for producing segmented RNA viruses, wherein the systems do not require bacteria for propagation of all of their expression constructs.
    Type: Application
    Filed: July 30, 2010
    Publication date: October 25, 2012
    Applicant: NOVARTIS AG
    Inventors: Philip Dormitzer, Michael Franti, Peter Mason
  • REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS
    Publication number: 20120189656
    Abstract: Expression of a transgene is driven in a host cell using a pol I promoter which is not endogenous to an organism from the same taxonomic order from which the host cell is derived.
    Type: Application
    Filed: May 21, 2010
    Publication date: July 26, 2012
    Inventors: Philip Dormitzer, Michael Franti, Peter Mason, Pirada Suphaphiphat, Bjoern Keiner, Stefania Crotta
  • MODIFIED GP140 ENVELOPE POLYPEPTIDES OF HIV-1 ISOLATES, COMPOSITIONS, STABILIZED TRIMERIC COMPLEXES, AND USES THEREOF
    Publication number: 20110250220
    Abstract: This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding such a polypeptide, vectors, host cells, trimeric complexes and compositions thereof.
    Type: Application
    Filed: May 4, 2011
    Publication date: October 13, 2011
    Inventors: Antu K. Dey, John P. Moore, William C. Olson, Sai Prasad N. Iyer, Yun (Kenneth) Kang, Michael Franti
  • Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain
    Patent number: 7939083
    Abstract: This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding such a polypeptide, vectors, host cells, trimeric complexes and compositions thereof.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: May 10, 2011
    Assignee: Progenics Pharmaceuticals Inc.
    Inventors: Antu K. Dey, John P. Moore, William C. Olson, Sai Prasad N. Iyer, Yun (Kenneth) Kang, Michael Franti
  • Soluble stabilized trimeric hiv env proteins and uses thereof
    Publication number: 20110076298
    Abstract: This invention provides a protein comprising (a) a first polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp120 envelope polypeptide portion of a gp140 envelope of (i) an HIV-I KNH1144 isolate, or a quasi-species thereof, or (ii) an HIV-I 5768.4 isolate, or a quasi-species thereof; and (b) a second polypeptide which comprises consecutive amino acids, the sequence of which corresponds to the sequence of a modified gp41 ectodomain polypeptide portion of the gp140 envelope of (i) the HIV-I KNH1144 isolate or such quasi-species thereof, or (ii) the HIV-I 5768.4 isolate or such quasi-species thereof. This invention also provides nucleic acids encoding such proteins, vectors, host cells and compositions thereof. Also provided are trimeric complexes (‘trimers’) of these proteins and methods of using such trimers to combat HIV-I infection.
    Type: Application
    Filed: June 19, 2007
    Publication date: March 31, 2011
    Inventors: William C. Olson, Paul J. Maddon, Michael Franti, Sai Prasad N. Iyer, Sofija Andjelic, John P. Moore, Simon Beddows
  • MODIFIED GP140 ENVELOPE POLYPEPTIDES OF HIV-1 ISOLATES, COMPOSITIONS, STABILIZED TRIMERIC COPLEXES, AND USES THEREOF
    Publication number: 20100041875
    Abstract: This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate comprising a gp120 polypeptide portion comprising consecutive amino acids and a gp41 ectodomain polypeptide portion comprising consecutive amino acids, said gp41 ectodomain polypeptide portion being modified to comprise isoleucine (I) at an amino acid position equivalent to amino acid position 535; glutamine (Q) at an amino acid position equivalent to amino acid position 543; serine (S) at an amino acid position equivalent to amino acid position 553; lysine (K) at an amino acid position equivalent to amino acid position 567; and arginine (R) at an amino acid position equivalent to amino acid position 588, the amino acid positions being numbered by reference to the HIV-1 isolate KNH1144. This invention also provides nucleic acids encoding such a polypeptide, vectors, host cells, trimeric complexes and compositions thereof.
    Type: Application
    Filed: October 17, 2007
    Publication date: February 18, 2010
    Inventors: Antu K. Dey, Moore P. John, William C. Olson, Sai Prasad N. Iyer, Yun (Kenneth) Kang, Michael Franti
  • Peptide from the glycoprotein B from human herpesvirus 7 for use in a serological ELISA test
    Publication number: 20050221299
    Abstract: The invention concerns an immunogenic peptide comprising at least six consecutive amino acids of a hydrophilic region of the glycoprotein B (gB) of the human herpesvirus-7 (HIV-7), and reacting specifically with antibodies directed against HHV-7, and diagnosis kit containing it.
    Type: Application
    Filed: May 23, 2005
    Publication date: October 6, 2005
    Inventors: Henri Agut, Michael Franti
  • Glycoprotein peptide of the human herpesvirus-7 for use in particular in an elisa serologic test
    Patent number: 6926899
    Abstract: The invention concerns an immunogenic peptide comprising at least six consecutive amino acids of a hydrophilic region of the glycoprotein B (gB) of the human herpesvirus-7 (HIV-7), and reacting specifically with antibodies directed against HHV-7, and diagnosis kit containing it.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: August 9, 2005
    Assignee: Universite Pierre et Marie Curie (Paris VI)
    Inventors: Henri Agut, Michael Franti
  • Glycoprotein peptide of the human herpesvirus-7 for use in particular in an elisa serologic test
    Publication number: 20040091852
    Abstract: The invention concerns an immunogenic peptide comprising at least six consecutive amino acids of a hydrophilic region of the glycoprotein B (gB) of the human herpesvirus-7 (HIV-7), and reacting specifically with antibodies directed against HHV-7, and diagnosis kit containing it.
    Type: Application
    Filed: June 13, 2003
    Publication date: May 13, 2004
    Inventors: Henri Agut, Michael Franti